iShares Expanded Tech Sector ETF (IGM)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more- Previous Close
142.98 - Open
143.48 - Bid 144.74 x 40000
- Ask 146.16 x 80000
- Day's Range
143.35 - 145.21 - 52 Week Range
93.79 - 145.22 - Volume
665,089 - Avg. Volume
836,629 - Net Assets 7.75B
- NAV 144.94
- PE Ratio (TTM) 38.38
- Yield 0.18%
- YTD Daily Total Return 12.27%
- Beta (5Y Monthly) 1.21
- Expense Ratio (net) 0.39%
Performance Overview: IGM
View MoreTrailing returns as of 5/1/2026. Category is Technology.
Holdings: IGM
View MoreTop 10 Holdings (53.53% of Total Assets)
Sector Weightings
Recent News: IGM
View MoreResearch Reports: IGM
View More-
Biogen Earnings: Strong First Quarter, Eventful Year Ahead
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
RatingPrice Target -
Biogen Earnings: Eventful Year Ahead Despite Expected Decline in Revenue
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
RatingPrice Target -
AI driving growth, raising target price to $450
Taiwan Semiconductor Manufacturing Company Ltd., headquartered in Hsinchu, Taiwan, was founded in 1987 and pioneered the pure-play foundry or 'merchant fab' model. The company serves both integrated semiconductor producers who outsource a portion of their production as well as 'fabless' semiconductor producers who outsource all manufacturing. Taiwan Semi serves over 500 semiconductor customers, producing more than 11,500 distinct products while providing a broad range of advanced, specialty, and advanced packaging technologies.
RatingPrice Target -
ASML Earnings: Outlook Is Magnificent, but Valuation Overshoots Our Fair Value Estimate
ASML is the leader in lithography systems for manufacturing semiconductors with 90% market share. Lithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. Lithography allows chipmakers to increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML’s largest clients are TSMC, Samsung, Intel, SK Hynix, and Micron.
RatingPrice Target


